1. Home
  2. DVAX vs LNN Comparison

DVAX vs LNN Comparison

Compare DVAX & LNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dynavax Technologies Corporation

DVAX

Dynavax Technologies Corporation

HOLD

Current Price

$10.94

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Lindsay Corporation

LNN

Lindsay Corporation

HOLD

Current Price

$118.49

Market Cap

1.2B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
DVAX
LNN
Founded
1996
1954
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2004
1988

Fundamental Metrics

Financial Performance
Metric
DVAX
LNN
Price
$10.94
$118.49
Analyst Decision
Buy
Hold
Analyst Count
4
1
Target Price
$26.50
$136.00
AVG Volume (30 Days)
1.7M
134.7K
Earning Date
11-05-2025
01-06-2026
Dividend Yield
N/A
1.24%
EPS Growth
N/A
12.81
EPS
N/A
6.78
Revenue
$330,514,000.00
$676,368,000.00
Revenue This Year
$24.63
N/A
Revenue Next Year
$15.85
$7.54
P/E Ratio
N/A
$17.53
Revenue Growth
26.73
11.41
52 Week Low
$9.20
$106.10
52 Week High
$14.63
$150.96

Technical Indicators

Market Signals
Indicator
DVAX
LNN
Relative Strength Index (RSI) 50.47 55.30
Support Level $10.79 $113.52
Resistance Level $11.10 $119.96
Average True Range (ATR) 0.31 3.24
MACD -0.07 1.45
Stochastic Oscillator 30.00 89.18

Price Performance

Historical Comparison
DVAX
LNN

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

About LNN Lindsay Corporation

Lindsay Corp provides proprietary water management and road infrastructure products and services. It manufactures and distributes agricultural irrigation equipment through two segments: Irrigation and Infrastructure. The Irrigation segment makes center pivot, lateral move, and hose reel irrigation systems and parts. The Infrastructure segment produces barriers, crash cushions, road marking and safety equipment, and railroad signals. The majority of revenue is from the Irrigation segment. The company operates in the United States and international markets, with the majority of revenue coming from the United States.

Share on Social Networks: